Ask about this productRelated genes to: SFRP1 antibody
- Gene:
- SFRP1 NIH gene
- Name:
- secreted frizzled related protein 1
- Previous symbol:
- -
- Synonyms:
- SARP2, FRP, FRP-1
- Chromosome:
- 8p11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1998-07-15
- Date modifiied:
- 2016-05-04
Related products to: SFRP1 antibody
Related articles to: SFRP1 antibody
- Fluid protein studies in cerebrospinal fluid (CSF) and plasma have provided important insights into neurodegenerative dementias; however, there is a limited investigation of sex-related differences and cross-biofluid relationships. In Alzheimer's disease (AD), Lewy body dementia (LBD), and frontotemporal dementia (FTD), large-scale, sex-stratified analyses of paired CSF and plasma samples remain scarce. Using the multiplex and ultrasensitive capabilities of NULISAseq™ technology, this study aims to characterize sex- and disease-specific proteomic alterations associated with Central Nervous System (CNS) pathology to explore underlying mechanisms. - Source: PubMed
Publication date: 2026/05/08
Comas-Albertí AinaLladó AlbertEsteller-Gauxax DianaBorrego-Écija SergiFalgàs NeusDakterzada FaridaPérez-Millan AgnèsPuey RogerCollet-Romà TàniaGuillén NúriaMassons MiquelTort-Merino AdriàAugé Josep MariaFernandez-Villullas GuadalupeBosch BeaRuiz-García RaquelNaranjo LauraBalasa MirceaPiñol-Ripoll GerardAntonell AnnaSánchez-Valle Raquel - The Wnt signaling pathway antagonist SFRP1 is frequently silenced by promoter DNA hypermethylation in colorectal cancer (CRC). MBD2, a DNA methylation reader, is known to contribute to SFRP1 epigenetic silencing. Previous work showed that MBD2 critically suppresses SFRP1 expression without altering promoter methylation, though the underlying mechanism remained unclear. Elucidating how DNA methylation silences tumor suppressor genes, such as , could reveal novel therapeutic targets with significant clinical potential. - Source: PubMed
Publication date: 2026/05/05
Huang XiujiLuo TingtingKe LinglingGuan ShaotingWu HuixianLi BoLiu YutingQi Jian - Human nephrogenesis is complete at 34-36 weeks gestation, with 60% of nephrons forming during the third trimester through lateral branch nephrogenesis (LBN). Currently, no mechanism exists for LBN as there are no late gestation human kidney transcriptional datasets. We hypothesized that an induced but dividing population of nephron progenitor cells (NPCs) would contribute to the amplification of nephrons in late gestation. We used the rhesus macaque, an established model of LBN, to help identify potential mechanisms. - Source: PubMed
Publication date: 2026/05/04
Thakkar KairaveeYarlagadda SunithaAlkhudairy LyanPotter AndrewThorner KonradChaturvedi PraneetCebrian CristinaMcCracken Kyle WSalomonis NathanKopan RaphaelSchuh Meredith P - Head and neck squamous cell carcinoma (HNSCC) exhibits heterogeneous responses to immunotherapy, primarily determined by the tumor immune microenvironment (TME). Accordingly, there is an urgent need for reliable biomarkers that can effectively distinguish between immune "hot" and "cold" tumors and predict prognosis and immunotherapy response. - Source: PubMed
Publication date: 2026/04/08
Li PianPang KelingZhou ZhigangYang ChaolinChen YiWu YangjieWang FujueHe Junyan - To investigate the diagnostic and prognostic value of CSPG4 and SFRP1 expression in esophageal basaloid squamous cell carcinoma (EBSCC). EBSCC cases in pathological diagnostic reports from Zhongshan Hospital, Fudan University from 2001 to 2023 were collected. Three senior pathologists independently reviewed the slides, and 81 cases of EBSCC and 55 conventional esophageal squamous cell carcinomas (ESCC) with consistent diagnoses were collected. Immunohistochemical staining for CSPG4 and SFRP1 was performed. The sensitivity and specificity of CSPG4 and SFRP1 expression in diagnosing EBSCC, as well as their correlation with prognosis, were analyzed. Among the 81 EBSCC and 55 conventional ESCC cases, there were no significant differences in patient gender, age, or surgical resection time (>0.05). The expression levels of CSPG4 and SFRP1 were significantly higher in EBSCC than in conventional ESCC (<0.001), with no significant differences across different invasive layers (>0.05). The receiver operating characteristic (ROC) curve for CSPG4 had an area under the curve (AUC) value of 0.952, with an optimal H-score cutoff of 75, showing a sensitivity of 92.6% and a specificity of 89.1% for diagnosing EBSCC. For SFRP1, the ROC curve had an AUC value of 0.880, with an optimal H-score cutoff of 1.5, showing a sensitivity of 81.5% and a specificity of 94.5%. When combined, CSPG4 and SFRP1 achieved a sensitivity of 80.2% and a specificity of 100% for diagnosing EBSCC. Among the 79 EBSCC cases with follow-up data, 17.7% showed high expression of both CSPG4 and SFRP1, 17.7% showed high CSPG4 but low SFRP1 expression, 13.9% showed low CSPG4 but high SFRP1 expression, and 50.6% showed low expression of both molecules. Compared to patients with low expression of both CSPG4 and SFRP1, those with high CSPG4 and low SFRP1 expression had the worst prognosis (disease-free survival: =0.190; overall survival: =0.031), particularly in stage Ⅰ-Ⅱ patients (disease-free survival: =0.031; overall survival: =0.013). CSPG4 and SFRP1 are primarily expressed in EBSCC. The combined application of immunohistochemical staining for these two markers can serve as a molecular indicator for the differential diagnosis and prognostic prediction of EBSCC. - Source: PubMed
Xiao Y HJiang D XYu Z XYuan WHuang JSong QZhang X LSu J A K SXu CHou Y Y